Synthesized peptide derived from human NCoA-3 (Acetyl Lys616)

This antibody detects endogenous levels of Human NCoA-3 (Acetyl Lys616).The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):ESkGH

NCOA3 AIB1 BHLHE42 RAC3 TRAM1

NCoA-3 (Acetyl Lys616)

NCOA3 ;
AIB1 ;
BHLHE42 ;
RAC3 ;
TRAM1 ;
Nuclear receptor coactivator 3 ;
NCoA-3 ;
ACTR ;
Amplified in breast cancer 1 protein ;
AIB-1 ;
CBP-interacting protein ;
pCIP ;
Class E basic helix-loop-helix protein 42 ;
bHLHe42 ;
Receptor-associated coactivator 3 ;
RAC-3 ;
Steroid receptor coactivator protein 3 ;
SRC-3 ;
Thyroid hormone receptor activator molecule 1 ;
TRAM-1

The protein encoded by this gene is a nuclear receptor coactivator that interacts with nuclear hormone receptors to enhance their transcriptional activator functions. The encoded protein has histone acetyltransferase activity and recruits p300/CBP-associated factor and CREB binding protein as part of a multisubunit coactivation complex. This protein is initially found in the cytoplasm but is translocated into the nucleus upon phosphorylation. Several transcript variants encoding different isoforms have been found for this gene. In addition, a polymorphic repeat region is found in the C-terminus of the encoded protein. [provided by RefSeq, Mar 2010],

Alternative products:Additional isoforms seem to exist,Catalytic activity:Acetyl-CoA + histone = CoA + acetylhistone.,Domain:Contains three Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. Motifs 1 and 2 are essential for the association with nuclear receptors, and constitute the RID domain (Receptor-interacting domain).,enzyme regulation:Coactivator activity on nuclear receptors and NF-kappa-B pathways is enhanced by various hormones, and the TNF cytokine, respectively. TNF stimulation probably enhances phosphorylation, which in turn activates coactivator function. In contrast, acetylation by CREBBP apparently suppresses coactivation of target genes by disrupting its association with nuclear receptors.,Function:Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit.,miscellaneous:NCOA3 is frequently amplified or overexpressed in breast and ovarian cancers.,polymorphism:The length of the poly-Gln region is polymorphic in the normal population.,PTM:Acetylated by CREBBP. Acetylation occurs in the RID domain, and disrupts the interaction with nuclear receptors and regulates its function.,PTM:Methylated by CARM1.,PTM:Phosphorylated by IKK complex. Regulated its function.,similarity:Belongs to the SRC/p160 nuclear receptor coactivator family.,similarity:Contains 1 basic helix-loop-helix (bHLH) domain.,similarity:Contains 1 PAS (PER-ARNT-SIM) domain.,subcellular location:Mainly cytoplasmic and weakly nuclear. Upon TNF activation and subsequent phosphorylation, it translocates from the cytoplasm to the nucleus.,subunit:Interacts with CARM1 (By similarity). Present in a complex containing NCOA2, IKKA, IKKB, IKBKG and the histone acetyltransferase protein CREBBP. Interacts with CASP8AP2, NR3C1 and PCAF. Interacts with ATAD2 and this interaction is enhanced by estradiol.,tissue specificity:Widely expressed. High expression in heart, skeletal muscle, pancreas and placenta. Low expression in brain, and very low in lung, liver and kidney.,

Cytoplasm. Nucleus. Mainly cytoplasmic and weakly nuclear. Upon TNF activation and subsequent phosphorylation, it translocates from the cytoplasm to the nucleus.

Widely expressed. High expression in heart, skeletal muscle, pancreas and placenta. Low expression in brain, and very low in lung, liver and kidney.

>>Endocrine resistance ;
>>Estrogen signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Pathways in cancer ;
>>Breast cancer